Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
76.72
+0.82 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
33
34
Next >
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
A Look Into Gilead Sciences Inc's Price Over Earnings
December 07, 2023
Via
Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
November 21, 2023
Via
Benzinga
Is NASDAQ:GILD suited for dividend investing?
November 20, 2023
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD).
Via
Chartmill
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
There's no time like the present to buy these stocks.
Via
The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied
Via
Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...
Via
Benzinga
Exposures
Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
November 17, 2023
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying.
Via
Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
November 15, 2023
Via
Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
November 09, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
November 09, 2023
Via
Benzinga
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
The companies will work together on treatments for multiple myeloma and lymphomas.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
November 07, 2023
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
Via
Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
November 07, 2023
GILD earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
November 06, 2023
Via
Benzinga
This Is What Whales Are Betting On Gilead Sciences
November 02, 2023
Via
Benzinga
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
November 07, 2023
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's
Via
Benzinga
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
November 07, 2023
The biotech company makes three notable treatments for cancer.
Via
Investor's Business Daily
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
November 07, 2023
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month...
Via
Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
November 07, 2023
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
November 03, 2023
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...
Via
Benzinga
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook
October 31, 2023
Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.
Via
Benzinga
3 Pharma Stocks That Are Screaming Buys in October
October 26, 2023
Each company delivers an above-average dividend and revenue growth.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.